Quick Answer
LIGAND PHARMACEUTICALS INC reported Diluted EPS of $6.13 per share for fiscal year 2025.
LIGAND PHARMACEUTICALS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $6.13 | +2886.4% |
| 2024 | -$0.22 | -107.5% |
| 2023 | $2.94 | +248.5% |
| 2022 | -$1.98 | -159.8% |
| 2021 | $3.31 | +1938.9% |
| 2020 | -$0.18 | -100.6% |
| 2019 | $31.85 | +434.4% |
| 2018 | $5.96 | +1024.5% |
| 2017 | $0.53 | +762.5% |
| 2016 | -$0.08 | -100.7% |
| 2015 | $10.83 | +1833.9% |
| 2014 | $0.56 | +1.8% |
| 2013 | $0.55 | +1933.3% |
| 2012 | -$0.03 | -106.1% |
| 2011 | $0.49 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.68 | +1556.4% | +2266.7% |
| June 30, 2025 | $0.24 | +108.3% | +110.9% |
| March 31, 2025 | -$2.21 | -146.5% | -466.7% |
| September 30, 2024 | -$0.39 | +33.9% | +86.5% |
| June 30, 2024 | -$2.88 | -2315.4% | -160.6% |
| March 31, 2024 | $4.75 | +103.9% | +905.1% |
| September 30, 2023 | -$0.59 | -3050.0% | -553.8% |
| June 30, 2023 | $0.13 | +360.0% | -94.4% |
- LIGAND PHARMACEUTICALS INC showed an increase of +2886.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, LIGAND PHARMACEUTICALS INC’s diluted eps has grown by 1151.0% (from $0.49 per share to $6.13 per share).
- The most recent figure is from LIGAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: